Phase II data shows CNV 1014802 (Convergence Pharmaceuticals) provides benefits for patients with Trigeminal Neuralgia

Interim data from the Phase II trial of CNV 1014802, from Convergence Pharmaceuticals, in patients with Trigeminal Neuralgia shows that the drug has a positive pharmacokinetic and safety profile for this pain condition. Eligible patients were entered into a 3-week open-label treatment period with CNV 1014802 at a dose of 150mg three times a day. If a successful response was observed in the final week of this period, patients were then randomised to a 4-week double-blind treatment period.

A planned interim analysis was performed once a pre-defined number of patients had completed the 3-week open-label treatment period. Success criteria for individual patient response was defined as a 30% or more reduction in numbers of paroxysms, or severity of paroxysms, relative to the run-in period. A total of 70% patients showed a successful response and were subsequently randomised into the double-blind treatment period. CNV 1014802 was well tolerated in these patients. Full clinical results are due at the end of 2013.